Porton Biologics Ltd. and Tianyu Life enter strategic collaboration to advance NK cell therapy research and commercialization

September 2, 2025, Suzhou — Porton Biologics Ltd. ("Porton Biologics") and Zhejiang Tianyu Life Science and Technology Co., Ltd. ("Tianyu Life") announced a strategic partnership.Jointly advance the research, development, and industrialization of NK cell therapy technology, committed to injecting new momentum into the development of the cell therapy field in China and even globally.

Porton Biologics Ltd. has rich project experience in the cell therapy field, establishing two NK induction and expansion process routes—with and without feeder cells—and has successfully supported client project delivery. It is China's first CDMO to provide CMCC and regulatory submission services for NK cells, successfully obtaining FDA clinical approval. Currently, multiple CAR-NK/NK IND projects are underway.According to the agreement, Porton Biologics Ltd. will provide process development, GMP manufacturing, and registration services for Tianyu Life's NK cell therapy project, assisting Tianyu Life’s NK cell therapeutic drug to successfully obtain clinical approval.Tianyu Life has deep technical accumulation and R&D strength in the NK cell therapy field, and this cooperation between the two parties will fully leverage their respective advantages to achieve a powerful synergy.

Technological Breakthrough: Driving Innovation Through Scientific Validation

Through years of independent research and development, Tianyu Life has successfully built the "One-in-a-Thousand" ultra-precision cell screening platform. This platform integrates AI-assisted screening with single-cell sequencing technology, enabling the precise selection of one donor with special biological activity NK cells from every 1,000 donors. According to Tianyu Life, multiple experiments have shown that the super NK cells obtained through screening exhibit outstanding characteristics in aging intervention, highly efficient anti-tumor activity, multi-organ protection functions, and long-lasting immune response.

Tianyu Life stated that the technology has laid a scientific foundation for industrialization, and in the future, it will strictly adhere to pharmaceutical R&D standards to systematically advance clinical and market transformation.

Industrial Synergy: Comprehensive Cooperation to Drive Implementation

Porton Biologics Ltd. will provide comprehensive process development and GMP manufacturing services for Tianyu Life's NK cell project, fully advancing the project in research and development, production, quality control, clinical submission, and commercial readiness.

Porton Biologics Ltd. has a comprehensive CDMO platform and extensive project experience, with a total R&D and production base area exceeding 20,000 square meters. It is equipped with 12 cell therapy production lines and 10 viral vector production lines, establishing a flexible, modular platform capable of supporting the production and testing of various types of cell therapy products.

As of August 2025, Porton Biologics Ltd. has received orders for 7 Phase I/II clinical projects and has cumulatively helped clients obtain 19 IND approvals globally, including China's first FDA-approved non-gene edited allogeneic peripheral blood NK cell drug for clinical trials.

This collaboration will inject new momentum into the research and development and commercial production of NK cell therapeutic drugs, potentially accelerating their market application in China.

Authoritative Viewpoint: Strong Alliance, Creating the Future Together

Wang Jianzhong, Chairman of Tianyu Life, said: "The successful screening of super NK cells is an important outcome of our team's decade-long research and development, overcoming three key technical challenges: the short survival time of NK cells in vivo, limited efficacy in treating solid tumors, and the integration of therapeutic and preventive functions. We look forward to completing clinical trials within three years and achieving large-scale production within five years through close cooperation with Porton Biologics Ltd.”

Hui Chen, Chief Financial Officer of Porton Advanced Solutions and Chief Executive Officer of Porton Biologics, stated: "We are very pleased to reach a strategic cooperation with Tianyu Life. The super NK cell technology of Tianyu Life is a significant breakthrough in the field of cell therapy. Porton Biologics Ltd. has successfully supported 16 cell therapy drugs in obtaining clinical approval and possesses an internationalized filing and production system. We believe this collaboration will significantly advance the industrialization process of China's cell therapy technology.。”

This strategic cooperation marks the in-depth collaboration between the two parties in the field of cell therapy. In the future, the two enterprises will continue to increase resource investment, jointly accelerate the research and development and industrialization of super NK cell therapy technology, and provide safer and more efficient treatment options for patients worldwide.

About Tianyu Life

Zhejiang Tianyu Life Science and Technology Co., Ltd. (NovaCell Therapeutics) was founded in July 2025 in Yuhang District, Hangzhou, by a team of top-tier Chinese-American scientists from Harvard, UCSF, WUSTL, and the University of Pittsburgh. The company focuses on the fields of cancer immunotherapy and cell regenerative medicine. Its core technology is the "super NK cells selected by natural evolutionary processes," with its self-developed "unique genotype high-activity super NK cells" showing 2-10 times higher activity than conventional NK cells, a survival cycle of 4-6 weeks, and dual "killing + repair" effects. These cells can combat cancer, delay aging, and improve liver damage and vascular health. Leveraging the synergistic advantages of the golden triangle of biomedicine in Hangzhou, Suzhou, and Shanghai: Hangzhou drives R&D through digital economy and AI technology, such as AI-based receptor omics analysis and simulation activation processes; Suzhou accelerates clinical translation and large-scale production via BioBay; Shanghai connects global resources through the International Medical Zone, promoting participation in international multicenter trials and commercialization. Guided by the philosophy of "natural gifts as the source, technological transformation as the wings," Tianyu Life Science and Technology is committed to providing safer and more effective health solutions for cancer patients, aging populations, and sub-healthy groups.

About Porton Biologics Ltd.

Porton Biologics Ltd., established in December 2018 and based in Suzhou, leverages its parent company, Porton Pharma Solutions (Stock Code: 300363), to provide global clients with one-stop service solutions covering the entire lifecycle of gene and cell therapy drugs—from preclinical research to commercialization. Porton Biologics has built CRO and CDMO platforms for plasmids, viral vectors, cell therapies, gene therapies, and nucleic acid therapies. It operates R&D and production facilities spanning over 20,000 square meters, with 10 viral vector production lines, 12 GMP cell therapy production lines (including two positive production workshops), and hundreds of cleanrooms. As of August 2025, Porton Biologics has supported clients in securing 19 clinical trial approvals globally, covering countries such as China, the United States, and New Zealand, with seven Phase I/II clinical projects underway, helping multiple overseas programs transition to China. We are committed to being customer-centric, delivering world-class, end-to-end CDMO services to accelerate life-saving medicines for patients worldwide.